Discontinued — last reported Q3 '22
Blackrock Acquisitions decreased by 100.0% to $0.00 in Q4 2025 compared to the prior quarter.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $47.25M | $47.25M | $47.25M | $47.25M | $0.00 | $74.00M | $3.12B | -$17.00M | $390.00M | $0.00 |
| QoQ Change | — | — | — | — | — | +0.0% | +0.0% | +0.0% | -100.0% | — | >999% | -100.5% | >999% | -100.0% |
| YoY Change | — | — | — | — | — | — | — | — | -100.0% | +56.6% | — | -123.0% | — | — |
We use cookies for analytics. See our Privacy and Cookie Policy.